Stock listing
Climb Bio, Inc.
Selected listing: CLYM · NASDAQ · USD · US
Climb Bio, Inc. (NASDAQ:CLYM), Health Technology. Latest release Oct 2, 2026: Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney…
- Ticker
- NASDAQ:CLYM
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Climb Bio, Inc.
The company focuses on biotechnology and aims to develop innovative solutions in its field. Climb Bio is committed to advancing its research and development efforts to contribute to the healthcare industry.
Latest news from Climb Bio, Inc.
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
October 2, 2026
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
October 1, 2026
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
September 3, 2026
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
June 11, 2026